📋 Tender Overview
Contract awarded for C/ base no cpa 2023_491 lot-0002, title: eculizumab 300 mg sol inj fr 30 ml iv, description: acquisition of 'eculizumab 300 mg sol inj fr 30 ml iv' lot-0014, title: blinatumomab 38.5 mg powder concentrate solution for injection iv, description: acquisition of blinatumomab 38.5 mg powder concentrate solution for injection iv estimated value excluding vat: 165656.80 eur.C/ base no cpa 2023_491